NFE2L2 and chronic kidney disease: Bardoxolone methyl (CDDO-Me), a potent Nrf2 activator, has been studied in clinical trials, and the phase III trial of CDDO-Me was terminated due to a higher rate of heart failure events in advanced chronic kidney disease patients40.